NYSE:AIM AIM ImmunoTech (AIM) Stock Forecast, Price & News $0.44 0.00 (0.00%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$0.43▼$0.4650-Day Range$0.40▼$0.5452-Week Range$0.29▼$1.05Volume82,152 shsAverage Volume64,258 shsMarket Capitalization$21.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media About AIM ImmunoTech (NYSE:AIM) StockAIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.Read More Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Email Address AIM Stock News HeadlinesMay 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and AIM ImmunoTech (AIM)May 15, 2023 | msn.comAIM ImmunoTech Q1 2023 Earnings PreviewJune 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 15, 2023 | msn.comEarnings Preview: AIM ImmunoTechMay 15, 2023 | finance.yahoo.comAIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline UpdateMay 15, 2023 | americanbankingnews.comAIM ImmunoTech (AIM) Scheduled to Post Earnings on TuesdayMay 9, 2023 | finance.yahoo.comAIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and WebcastApril 22, 2023 | americanbankingnews.comAnalyzing Palisade Bio (NASDAQ:PALI) & AIM ImmunoTech (NYSE:AIM)June 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.April 12, 2023 | finance.yahoo.comAIMIA'S LARGEST SHAREHOLDER REMINDS FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD PRIOR TO PROXY VOTING DEADLINEApril 12, 2023 | finance.yahoo.comAIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)April 10, 2023 | finance.yahoo.comAIMIA'S LARGEST SHAREHOLDER ENCOURAGES FELLOW SHAREHOLDERS TO VOTE AGAINST BOARDApril 9, 2023 | finance.yahoo.comAIM ImmunoTech Inc. (AMEX:AIM) Q4 2022 Earnings Call TranscriptApril 7, 2023 | markets.businessinsider.comAscendiant Remains a Buy on AIM ImmunoTech (AIM)April 5, 2023 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateApril 5, 2023 | markets.businessinsider.comMaxim Group Sticks to Their Buy Rating for AIM ImmunoTech (AIM)March 30, 2023 | tmcnet.comAIM ImmunoTech Bolsters Board of Directors with AppointmentMarch 30, 2023 | msn.comAIM ImmunoTech Earnings PreviewMarch 27, 2023 | finance.yahoo.comAIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and WebcastMarch 26, 2023 | americanbankingnews.comAIM ImmunoTech (NYSE:AIM) Trading Down 4.2%March 17, 2023 | baystreet.caBiotech Sector Delivering Increased Optimism in Battle Against Pancreatic CancerMarch 16, 2023 | tmcnet.comAIM ImmunoTech Announces Late-Breaking Presentation at theMarch 16, 2023 | finance.yahoo.comAIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus DiseaseMarch 8, 2023 | tmcnet.comAIM ImmunoTech Announces Publication of New Analysis ofMarch 6, 2023 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Issues Letter to StockholdersFebruary 28, 2023 | finance.yahoo.comAIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting PatientsFebruary 17, 2023 | tmcnet.comAIM ImmunoTech to Participate in Solve M.E.See More Headlines AIM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AIM Company Calendar Last Earnings4/03/2023Today6/04/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSE:AIM CUSIPN/A CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees21Year Founded1990Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,440,000.00 Net Margins-12,362.82% Pretax Margin-12,362.82% Return on Equity-47.58% Return on Assets-44.05% Debt Debt-to-Equity RatioN/A Current Ratio18.05 Quick Ratio18.05 Sales & Book Value Annual Sales$157,000.00 Price / Sales137.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book0.63Miscellaneous Outstanding Shares48,408,000Free Float48,398,000Market Cap$21.54 million OptionableNot Optionable Beta-0.30 Social Links Key ExecutivesThomas Kenwood EquelsExecutive Vice Chairman, President & CEOPeter W. RodinoCOO, Secretary & General CounselRobert DickeyChief Financial OfficerDavid R. StrayerChief Medical OfficerChristopher McAleerChief Scientific OfficerKey CompetitorsEntera BioNASDAQ:ENTXHarpoon TherapeuticsNASDAQ:HARPMiromatrix MedicalNASDAQ:MIROZIVO BioscienceNASDAQ:ZIVOERYTECH PharmaNASDAQ:ERYPView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCBought 31,800 shares on 5/12/2023Ownership: 0.349%Thomas K EquelsBought 161,291 shares on 1/3/2023Total: $50,000.21 ($0.31/share)Stewart AppelrouthBought 80,646 shares on 1/3/2023Total: $25,000.26 ($0.31/share)View All Insider TransactionsView All Institutional Transactions AIM Stock - Frequently Asked Questions How have AIM shares performed in 2023? AIM ImmunoTech's stock was trading at $0.3119 at the beginning of the year. Since then, AIM stock has increased by 42.7% and is now trading at $0.4450. View the best growth stocks for 2023 here. When is AIM ImmunoTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our AIM earnings forecast. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSE:AIM) released its quarterly earnings data on Monday, April, 3rd. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $0.06 million for the quarter. AIM ImmunoTech had a negative net margin of 12,362.82% and a negative trailing twelve-month return on equity of 47.58%. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX). What is AIM ImmunoTech's stock symbol? AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM." Who are AIM ImmunoTech's major shareholders? AIM ImmunoTech's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.35%). Insiders that own company stock include Stewart Appelrouth, Thomas K Equels and Thomas K Equels. View institutional ownership trends. How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AIM ImmunoTech's stock price today? One share of AIM stock can currently be purchased for approximately $0.45. How much money does AIM ImmunoTech make? AIM ImmunoTech (NYSE:AIM) has a market capitalization of $21.54 million and generates $157,000.00 in revenue each year. The company earns $-19,440,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. How can I contact AIM ImmunoTech? AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The official website for the company is aimimmuno.com. The company can be reached via phone at (352) 448-7797, via email at ir@aimimmuno.com, or via fax at 215-988-1739. This page (NYSE:AIM) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.